Valion Bio, Inc.
Research Valion Bio, Inc. (VBIO) on Bullrun: market cap USD 194.34K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVBIO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 194.34K
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 7.10M
- Free cash flow-USD 5.34M
Valuation Snapshot
latest market cap is USD 194.34K.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 8.88M | -USD 7.58M | n/a | -196 | USD 12.65M | USD 6.45M | USD 16.80M |
| FY2024 | USD 0 | -USD 5.66M | -USD 5.73M | n/a | -492 | USD 2.00M | USD 0 | USD 2.54M |
| FY2023 | USD 1.18M | -USD 8.24M | -USD 8.63M | 24.4% | -4420 | USD 3.40M | USD 369.00K | USD 3.58M |
| FY2022 | USD 1.84M | -USD 10.10M | -USD 8.93M | 16.3% | -44475.77 | USD 3.52M | USD 530.00K | USD 3.63M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-16 | USD 194.34K | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 91.56M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.28M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 65.94M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 155.04M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 32.98M | n/a | n/a | n/a |
About Valion Bio, Inc.
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Valion Bio, Inc.'s market cap?
Valion Bio, Inc.'s market capitalization is USD 194.34K.
What does Valion Bio, Inc. do?
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026.